99m Tc-FAPI SPECT/CT Provides Superior Diagnostic Performance to 18 F-FDG in Poorly Differentiated Gastric Adenocarcinoma.

Clin Nucl MedJun 23, 2026 (epub)
Case ReportOncology (Medical)Gastroenterology

Mohammad Hadi Samadi, Kamran Aryana, Ehsan Soltani et al.

✦ AI-curated · Sources linked

Case in brief

A 52-year-old woman with poorly differentiated gastric adenocarcinoma experienced early satiety following gastrectomy and chemotherapy. Initial imaging with CT and FDG PET/CT did not clearly indicate recurrence. However, a 99m Tc-FAPI SPECT/CT scan successfully identified all peritoneal and omental metastatic deposits, including small lesions overlooked by other modalities, thereby guiding further management.

Diagnostic / clinical pearl

99m Tc-FAPI SPECT/CT is particularly effective in detecting metastatic lesions in poorly differentiated gastric adenocarcinoma, especially when FDG uptake is limited.

Why it matters

This case underscores the potential of FAPI imaging to enhance detection of recurrence in challenging cases, which may influence treatment decisions.

Source

PubMed · PMID 42329090

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.